RAINBOW - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.7
| Stock Code | RAINBOW | Market Cap | 12,718 Cr. | Current Price | 1,252 ₹ | High / Low | 1,646 ₹ |
| Stock P/E | 51.9 | Book Value | 156 ₹ | Dividend Yield | 0.24 % | ROCE | 18.3 % |
| ROE | 16.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,222 ₹ | DMA 200 | 1,293 ₹ |
| Chg in FII Hold | -2.00 % | Chg in DII Hold | 1.63 % | PAT Qtr | 65.8 Cr. | PAT Prev Qtr | 73.2 Cr. |
| RSI | 54.5 | MACD | 18.9 | Volume | 72,911 | Avg Vol 1Wk | 1,01,882 |
| Low price | 1,009 ₹ | High price | 1,646 ₹ | PEG Ratio | 2.91 | Debt to equity | 0.46 |
| 52w Index | 38.2 % | Qtr Profit Var | -1.73 % | EPS | 24.2 ₹ | Industry PE | 47.1 |
📊 RAINBOW shows strong operational efficiency with ROCE (18.3%) and ROE (16.7%), supported by manageable debt-to-equity (0.46). EPS of ₹24.2 reflects earnings strength, but valuations are stretched with a P/E of 51.9 vs industry average of 47.1. Dividend yield is very low at 0.24%, and PEG ratio of 2.91 indicates growth is expensive. Quarterly PAT declined (-1.73%), raising caution. Overall, RAINBOW is a moderately strong healthcare company, but entry timing is crucial given premium valuations.
💡 Ideal Entry Price Zone: ₹1,220 – ₹1,240 (near DMA 50 and below current levels for valuation comfort).
⏳ Exit Strategy / Holding Period: Long-term investors can hold for 3–5 years. Partial profit booking is advisable near ₹1,600–₹1,640 (recent highs). Stop-loss can be considered around ₹1,200 to manage downside risk.
✅ Positive
- Strong ROCE (18.3%) and ROE (16.7%).
- EPS of ₹24.2 reflects earnings strength.
- DII holdings increased (+1.63%), showing domestic institutional support.
- MACD positive (18.9) indicates bullish momentum.
⚠️ Limitation
- High P/E (51.9) compared to industry average (47.1).
- PEG ratio (2.91) indicates expensive growth.
- Dividend yield low at 0.24%.
- Quarterly PAT declined (-1.73%).
📉 Company Negative News
- FII holdings reduced (-2.00%).
- Quarterly profit decline shows earnings pressure.
📈 Company Positive News
- Strong capital efficiency with ROCE and ROE above industry averages.
- DII inflows indicate domestic confidence.
- Stock delivered 38.2% gain over the past year.
🏭 Industry
- Industry P/E: 47.1, highlighting RAINBOW’s premium valuation.
- Healthcare sector supported by rising demand for specialized medical services.
🔎 Conclusion
RAINBOW is a fundamentally strong healthcare company with efficient capital use, but premium valuations and declining profits limit upside. New investors should wait for entry around ₹1,220–₹1,240 for safety. Existing holders can maintain a 3–5 year horizon, with partial profit booking near ₹1,600–₹1,640. Monitoring PEG ratio and profit growth will be key for sustained performance.